Halozyme Accounts Payable from 2010 to 2024
| HALO Stock | USD 44.29 0.94 2.17% |
Accounts Payable | First Reported 2002-03-31 | Previous Quarter 11.8 M | Current Value 13.3 M | Quarterly Volatility 4 M |
Check Halozyme Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Halozyme main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.1 M, Interest Expense of 19.7 M or Selling General Administrative of 156.6 M, as well as many exotic indicators such as Price To Sales Ratio of 5.59, Dividend Yield of 0.0 or PTB Ratio of 55.27. Halozyme financial statements analysis is a perfect complement when working with Halozyme Therapeutics Valuation or Volatility modules.
Halozyme | Accounts Payable |
Latest Halozyme Therapeutics' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Halozyme Therapeutics over the last few years. An accounting item on the balance sheet that represents Halozyme Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Halozyme Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Halozyme Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Halozyme Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Halozyme Accounts Payable Regression Statistics
| Arithmetic Mean | 5,861,454 | |
| Geometric Mean | 3,486,530 | |
| Coefficient Of Variation | 83.17 | |
| Mean Deviation | 3,824,792 | |
| Median | 4,079,000 | |
| Standard Deviation | 4,874,803 | |
| Sample Variance | 23.8T | |
| Range | 17.7M | |
| R-Value | 0.60 | |
| Mean Square Error | 16.3T | |
| R-Squared | 0.36 | |
| Significance | 0.02 | |
| Slope | 657,325 | |
| Total Sum of Squares | 332.7T |
Halozyme Accounts Payable History
About Halozyme Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Halozyme Therapeutics income statement, its balance sheet, and the statement of cash flows. Halozyme Therapeutics investors use historical funamental indicators, such as Halozyme Therapeutics's Accounts Payable, to determine how well the company is positioned to perform in the future. Although Halozyme Therapeutics investors may use each financial statement separately, they are all related. The changes in Halozyme Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Halozyme Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Halozyme Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Halozyme Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 11.8 M | 12.4 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Halozyme Therapeutics Correlation against competitors. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Halozyme Stock analysis
When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.069 | Earnings Share 2.41 | Revenue Per Share 6.643 | Quarterly Revenue Growth 0.208 | Return On Assets 0.1348 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.